ARGX vs MRNA
argenx SE and Moderna, both Healthcare
Moderna is the larger company at $82B against $55B. Over the past year MRNA returned +658% against +3.8% for ARGX.
| Figure | ARGX | MRNA |
|---|---|---|
| Last close | $882 | $207 |
| Market cap | $55B | $82B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 45.1 | n/a |
| 1-year return | +3.8% | +658% |
| 5-year return | +199% | -36% |
| RyuScoresector-relative, 1–10 | 11/100 | n/a |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 63% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.